Announcement: Aurelia Bioscience has been acquired by Charnwood Molecular.

Gary brings together innovative technology from R&D partners with client projects to create synergies and novel readouts, improving assay quality and reducing client project SAR cycle times. He leverages over 30 years of pre-clinical drug discovery experience and a number of scientific papers in leading journals to aid the discovery of new chemical entities.

Qualifications.

After gaining his Ph.D. from Edinburgh University in 1990, Gary joined Hoffmann La Roche (USA) to investigate retinoid pharmacology and the role of nuclear hormone receptors in foetal development. He then went on to work in the Lead Generation Section of GSK (UK) in 1995, gaining expertise in the development of cell-based assays within the CNS disease area for high throughput screening as well as novel drug discovery assay technologies and automation.

Specialisms.

After leaving GSK, Gary spent over 10 years at AstraZeneca (UK), developing novel cell-culture robotics and evaluating and implementing new assay technologies for respiratory and inflammatory diseases, before founding Aurelia Bioscience.